The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Open accessAbstract
Persistent antiphospholipid (aPL) antibodies are occasionally found in subjects without prior history of thromboembolic events (TEs), raising the dilemma of whether to initiate or not a primary thromboprophylaxis. A first TE is considered rare in aPL carriers, but previous studies did not consider the aPL profile nor was the test positivity confirmed in a reference laboratory. In this study, 104 subjects with high-risk aPL profile (positive lupus anticoagulant, anticardiolipin, and anti-β2–glycoprotein I antibodies, triple positivity) confirmed in a reference laboratory, were followed up for a mean of 4.5 years. There were 25 first TEs (5.3% per year): the cumulative incidence after 10 years was 37.1% (95% confidence interval [CI], 19.9%-54.3%). On multivariate analysis, male sex (hazard ratio = 4.4; 95% CI, 1.5-13.1, P = .007) and risk factors for venous thromboembolism (hazard ratio = 3.3; 95% CI, 1.3-8.5, P = .01) were independent predictors for TEs. Aspirin did not significantly affect the incidence of TE. In conclusion, the occurrence of a first TE in carriers of high-risk aPL profile is considerable; it is more frequent among male subjects and in the presence of additional risk factors for venous TE. These data can help in the decision to initiate primary thromboprophylaxis in these subjects.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In 104 asymptomatic carriers of triple-positive antiphospholipid antibodies confirmed in a reference laboratory, first thromboembolic events occurred at 5.3% per year, with a 10-year cumulative incidence of 37.1%. Male sex and venous thromboembolism risk factors independently predicted events, whereas aspirin did not significantly reduce them.
Key findings
- During 469 patient-years of follow-up, there were 25 first thromboembolic events (5.3% per year); cumulative incidence was 9.8% (95% CI, 3.7%-15.9%) at 2 years, 27.3% (95% CI, 17.1%-37.5%) at 5 years, and 37.1% (95% CI, 19.9%-54.3%) at 10 years.
- On multivariate analysis, independent predictors of thromboembolism were male sex (hazard ratio 4.4; 95% CI, 1.5-13.1; P = .007) and presence of risk factors for venous thromboembolism (hazard ratio 3.3; 95% CI, 1.3-8.5; P = .01).
- Aspirin prophylaxis did not significantly affect thromboembolic events on multivariate analysis (hazard ratio 0.5; 95% CI, 0.2-1.5; P = .2); it was close to significance on univariate analysis but did not achieve statistical significance.
- Among the 25 events, there were 12 arterial and 11 venous thromboembolic events, 1 right atrial thrombosis, and 1 renal thrombotic microangiopathy.
Methods
- Multicenter prospective cohort of 104 subjects with high-risk antiphospholipid antibody profile (triple positivity: lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies) on 2 occasions at least 12 weeks apart, without clinical features of antiphospholipid syndrome; triple positivity was confirmed in a reference laboratory. Mean age was 45 years, 79% were female, and mean follow-up was 4.5 years.
- Subjects were seen annually or earlier as clinically indicated; no long-term anticoagulant treatment was prescribed, and short-term low-molecular-weight heparin was given in high-risk thromboembolism scenarios. Data collected included demographic, laboratory, and clinical variables, autoimmune disease, arterial and venous risk factors, and aspirin treatment.
- Kaplan-Meier survival analysis estimated cumulative incidence of thromboembolism; Cox regression survival analysis identified predictors among demographic factors, autoimmune diseases, anticardiolipin isotype, arterial and venous risk factors, and aspirin treatment. Statistical significance was set at P < .05; analyses used SPSS.
Limitations
- The paper does not include a formal limitations section. It states that larger clinical trials are definitely needed to test hypotheses about aspirin and hydroxychloroquine.
- Evident from the text: treatment with aspirin was observational rather than randomized, so confounding by indication cannot be excluded; the cohort had 104 subjects and 25 events, yielding wide confidence intervals for some estimates.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Own result · 7 No full text of the sources · 4 Own interpretation · 3 Own method · 2 Partly supported · 1 Supported so far · 1 Couldn’t confirm · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“that (1.36%) of 125 single aPL positive carriers with a mean age of 41 years (data taken by a recently published study by our group), 15”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Could not verifycites [15] Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study., Ann Rheum Dis sourceExperimental — accuracy not yet measured
The Results and Discussion report an annual thrombosis incidence of 1.86 per 100 patients for the full cohort of 258 aPL carriers. Searches for 125 single-positive carriers and a 1.36% annual rate found no passage reporting that subgroup rate; the overall rate does not establish or contradict it. (LLM, conf=0.73)
plainn = 125- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the higher incidence of TEs recorded in this study may be related to the selection of high-risk aPL-positive population”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Partly supportedcites [15] Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study., Ann Rheum Dis sourceExperimental — accuracy not yet measured
The Analysis of risk factors for thrombosis identifies hypertension and lupus anticoagulant as independent predictors of thrombotic events, supporting the premise that risk profile matters. The Discussion describes this source paper’s own event rate as low and similar to other studies; it does not assess whether selection of a high-risk population explains the higher incidence in the citing study. Page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [16] Mok, 2005, Incidence and risk factors of thromboembolism systemic lupus erythematosus: a comparison of three ethnic groups., Arthritis Rheum source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 18 patients treated with hydroxychloroquine, 2 (11%) had a first TE in the follow-up period.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“male sex (hazard ratio ϭ 4.4; 95% CI, 1.5-13.1,P ϭ .007)and the presence of factors predisposing to VTE (hazard ratio ϭ 3.3; 95% CI, 1.3-8.5,P ϭ .01)were found to be independent predictors for clinical events”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plaincorrelationaln = 25 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Aspirin prophylaxis was close to significance in reducing events on univariate analysis but did not achieve statistical significance on multivariate analysis (hazard ratio ϭ 0.5; 95% CI, 0.2-1.5,P ϭ .2)”
- Also stated in: § Abstract · plain
“As-pirin did not significantly affect the incidence of TE.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 25- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“27.3% (95% CI, 17.1%-37.5%)after 5 years”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“male sex (hazard ratio ϭ 4.4; 95% CI, 1.5-13.1,P ϭ .007)and the presence of factors predisposing to VTE (hazard ratio ϭ 3.3; 95% CI, 1.3-8.5,P ϭ .01)were found to be independent predictors for clinical events”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plaincorrelationaln = 25 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the cumulative incidence after 10 years was 37.1% (95% confidence interval [CI], 19.9%-54.3%)”
- Also stated in: § Results · plain
“and 37.1% (95% CI, 19.9%-54.3%)after 10 years (Figure 1).”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, 104 subjects with high-risk aPL profile (positive lupus anticoagulant, anticardiolipin, and anti- 2 -glycoprotein I antibodies, triple positivity) confirmed in a reference laboratory, were followed up for a mean of 4.5 years.There were 25 first TEs (5.3% per year)”
- Also stated in: § Results · plain
“During a total follow-up of 469 years, there were 25 TEs (5.3% per year).”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cumulative incidence of TEs was 9.8% (95% confidence interval [CI], 3.7%-15.9%)after 2 years”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 3
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the annual rate (ϳ 0.4%) of first cardiovascular event (including VTE) in normal white population at 35 to 55 years of age, 14”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Partly supportedcites [14] Roger, 2011, Heart disease and stroke statistics: 2011 update. A report from the American Heart Association., Circulation sourceExperimental — accuracy not yet measured
The Cardiovascular Diseases > Incidence section reports 3 first cardiovascular events per 1,000 men annually at ages 35–44, which is close to the claimed 0.4%. It does not give a single rate for a healthy white population aged 35–55. The Venous Thromboembolism > Incidence section reports VTE separately, not as part of that first-event rate; page numbers were not supplied. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“triple positivity (all 3 tests positive) is associated with thrombosis and identifies high-risk patients with aPL syndrome (APS).6,7”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Introduction
What the sources say
- Not checked — no full text of the sourcecites [6] Pengo, 2005, Antibody profiles for the diagnosis of antiphospholipid syndrome., Thromb Haemost source
- Supportedcites [7] Pengo, 2009, Clinical course of high risk patients diagnosed with antiphospholipid syndrome (APS)., J Thromb Haemost source
The Discussion states that patients positive on all three laboratory tests are at higher risk of thrombosis. The Introduction reports a marked association between multiple positivity and thromboembolic events, and the Discussion describes the triple-positive APS cohort as high-risk. Page numbers are not provided in our copy. (LLM, conf=0.93)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Venous thromboembolism (VTE) was diagnosed by compression ultrasonography or venography in case of deep vein thrombosis, and spiral tomography, ventilation-perfusion lung scan, or pulmonary angiography in case of pulmonary embolism.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Outcome events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data can help in the decision to initiate primary thromboprophylaxis in these subjects.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Rests on an assumption: The clinical course of persons carrying a high-risk antiphospholipid antibody profile (triple positivity) is not known.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it is more frequent among male subjects and in the presence of additional risk factors for venous TE”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“That male sex is related to a higher risk for recurrence of VTE among patients with unprovoked deep vein thrombosis is not new.25”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Discussion
What the sources say
- Not checked — no full text of the sourcecites [25] McRae, 2006, Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis., Lancet source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was approved by the local ethics committee of each Thrombosis Center.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“plasma from patients of each center was retested in a reference laboratory (Padua Thrombosis Center).Final inclusion in the cohort required confirmation of LA positivity as well as aCL and anti- 2 GPI antibody positivity (values in the upper 99th percentile of 40 healthy subjects) for the same isotype.”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
plainn = 40- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
The paper relies on this without support.
The clinical course of persons carrying a high-risk antiphospholipid antibody profile (triple positivity) is not known.
“The clinical course in persons with high-risk aPL antibody profile (triple positivity) is not known, casting a shadow on the need for primary prophylaxis to avoid TEs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“aPL profiling also involves consideration of antibody titers since higher titers are associated with higher risk [7,8,30,31].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients positive for the combination of LAC, antiβ 2GPI, and anti-CL antibodies,theso-called triple-positive patients, exhibit a high risk for developing a first thrombotic event and recurrence of thrombosis. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“andpatientspositiveforallthree aPLs are identified as individuals at high risk for a first clinical event and for recurrence. 8,9”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note is that many studies on triple positivity merely report patients as being positive for LA without assessing dRVVT and APTT results separately [10,[23][24][25][26][27][28][29], or even use only 1 assay [7,8,12].”
From Triple-positive antiphospholipid syndrome does not guarantee positivity in each lupus anticoagulant assay (2023) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“it has been demonstrated that asymptomatic persistent carriers of LA and of the other antiphospholipid antibodies have a higher risk of future thromboembolic events [11,12].”
From Lupus Anticoagulant Detection under the Magnifying Glass (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, persistent aPL positivity can also be found in the absence of clinical criteria of APS in patients called 'aPL carriers,' raising the dilemma of initiating or not a primary thromboprophylaxis. 19,20”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Results
“IgM aCL, GPL units (mean Ϯ SD) 1.42 Ϯ 0.3”
§ THROMBOSIS AND HEMOSTASIS Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study > Study design and population
“The predominant isotype was considered M when IgM aCL value expressed as MPL units exceeded the IgG aCL value (expressed as GPL units).”
Citations
Cites
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Update of the guidelines for lupus anticoagulant detection
PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03555.x · Cited by 1,197
Self-citationGalli, M., Luciani, D., Bertolini, G., & Barbui, T. (2003) · Blood · doi:10.1182/blood-2002-02-0441 · Cited by 972
Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome
PENGO, V., RUFFATTI, A., LEGNANI, C., GRESELE, P., BARCELLONA, D., ERBA, N., TESTA, S., MARONGIU, F., BISON, E., DENAS, G., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03674.x · Cited by 632
Self-citationErkan, D., Harrison, M. J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp‐Arida, A., Vilela, V., Yazici, Y., & Lockshin, M. D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22663 · Cited by 401
Antibody profiles for the diagnosis of antiphospholipid syndrome
Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., & Pengo, V. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0839 · Cited by 318
Self-citationEffect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.
McRae, S., Tran, H., Schulman, S., Ginsberg, J., & Kearon, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69110-1 · Cited by 289
Mok, C. C., Tang, S. S. K., To, C. H., & Petri, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21224 · Cited by 237
(2004) · PubMed · Cited by 218
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis
DE GROOT, P. G., LUTTERS, B., DERKSEN, R. H. W. M., LISMAN, T., MEIJERS, J. C. M., & ROSENDAAL, F. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01485.x · Cited by 205
Cited by
Sorted by citations
Items 201–300 of 462
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers
Chaturvedi, S., & McCrae, K. R. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0668-2 · Cited by 17
Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's
Arnaud, L., Conti, F., Massaro, L., Denas, G., Chasset, F., & Pengo, V. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.09.003 · Cited by 16
Self-citationLaboratory Diagnosis of the Lupus Anticoagulant
Ortel, T. L. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0225-3 · Cited by 17
Antiphospholipid syndrome: Looking for a refocusing
Gris, J., & Bouvier, S. (2013) · Thrombosis Research · doi:10.1016/s0049-3848(13)70016-1 · Cited by 15
Finazzi, G. (2012) · Lupus · doi:10.1177/0961203312437440 · Cited by 15
The Laboratory Diagnosis of the Antiphospholipid Syndrome
Ahluwalia, J., & Sreedharanunni, S. (2016) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-016-0739-y · Cited by 15
“37 % at 10 years) [14, 15].”
Thrombotic microangiopathies: Similar presentations, different therapies
Appel, G. B. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17001 · Cited by 15
Diagnostic biologique du syndrome des antiphospholipides : des critères à la pratique
Joste, V., Dragon‐Durey, M., & Darnige, L. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.02.006 · Cited by 15
Tonello, M., Mattia, E., Ross, T. D., Favarò, M., Calligaro, A., Hoxha, A., Bison, E., Pengo, V., & Ruffatti, A. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.06.037 · Cited by 15
Self-citationThe assessment of patients with the antiphospholipid antibody syndrome: where are we now?
Gaspar, P., Cohen, H., & Isenberg, D. A. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa172 · Cited by 15
Antiphospholipid Syndrome: State of the Art of Clinical Management
Depietri, L., Veropalumbo, M. R., Leone, M. C., & Ghirarduzzi, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07496-3 · Cited by 16
“…must be identified with the triple-positive patients as they are at the highest risk for both a first thrombotic event and a higher rate of recurrence despite antithrombotic treatment [23, 24] and that any other combination of positivity should be regarded as low to moderate thrombotic risk.”
Self-citationBernardi, M., Spadafora, L., Andaloro, S., Piscitelli, A., Fornaci, G., Intonti, C., Fratta, A. E., Hsu, C.-E., Kaziród-Wolski, K., Metsovitis, T., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113064 · Cited by 16
“[9,70,74] and is associated with an increased risk of cardiovascular complications [75,76].”
BackgroundAntiphospholipid syndrome and its role in pediatric cerebrovascular diseases: A literature review
Sarecka‐Hujar, B., & Kopyta, I. A. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i10.1806 · Cited by 14
Frodlund, M., Walhelm, T., Dahle, C., & Sjöwall, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.646846 · Cited by 16
Meschia, J. F., Bushnell, C., Boden-Albala, B. M., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Fornage, M., Goldstein, L. B., et al. (2014) · Cited by 15
Prevention of Pregnancy Complications in Antiphospholipid Syndrome
Czwalinna, A., & Bergmann, F. (2020) · Hämostaseologie · doi:10.1055/a-1113-0689 · Cited by 14
Tonello, M., Calligaro, A., Favarò, M., Ross, T. D., Veronese, P., Salvan, E., Gervasi, M. T., & Ruffatti, A. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05766-1 · Cited by 14
Self-citationDiagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant
Tripodi, A. (2021) · Biomedicines · doi:10.3390/biomedicines9070844 · Cited by 14
“, concomitant positivity for LA, aCL and aβ2-GP-I) identifies patients at high risk of clinical events [3].”
BackgroundIschemic Stroke: An Underestimated Complication of COVID-19
Cao, W., Zhang, C., Wang, H., Wu, Q., Yuan, Y., Chen, J., Geng, S., & Zhang, X. (2021) · Aging and Disease · doi:10.14336/ad.2021.0209 · Cited by 14
“1% (after 10 years) during the follow-up period [85].”
Figueroa‐Parra, G., Meade‐Aguilar, J. A., Langenfeld, H. E., González‐Treviño, M., Hocaoǧlu, M., Hanson, A. C., Prokop, L. J., Murad, M. H., Cartin‐Ceba, R., Specks, U., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109775 · Cited by 13
How to diagnose and manage antiphospholipid syndrome
Hubben, A. K., & McCrae, K. R. (2023) · Hematology · doi:10.1182/hematology.2023000493 · Cited by 16
Ugarte, A., de Bustos, A. G., Ruiz‐Arruza, I., Soto-Peleteiro, A., Martín‐Iglesias, D., González-Echávarri, C., & Ruiz‐Irastorza, G. (2021) · Rheumatology · doi:10.1093/rheumatology/keab307 · Cited by 13
Traitement du syndrome des anticorps antiphospholipides
Saadoun, D., Pietté, J. C., Wahl, D. G., & Costedoat-Chalumeau, N. (2012) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2012.01.007 · Cited by 12
Boháčeková, M., Kaldarárová, M., Valkovičová, T., et al. (2016) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2016_112 · Cited by 13
Pine, A. B., Butt, A., Andréoli, L., Knight, J. S., Gerosa, M., Cecchi, I., Branch, D. W., Lopez-Pedrera, R., Belmont, M. H., Kello, N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676578 · Cited by 12
Self-citationRicard, L., Laurent, C., Papo, M., Deriaz, S., Catano, J., Alamowitch, S., Kayem, G., Chasset, F., MOREUIL, C. D., Boffa, J. J., et al. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105297 · Cited by 14
Clinical profiles and risk assessment in patients with antiphospholipid antibodies
Kato, M., Hisada, R., & Atsumi, T. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1543025 · Cited by 13
Ruffatti, A., Tonello, M., Calligaro, A., Ross, T. D., Favarò, M., Zen, M., Carletto, A., Lotti, V., Bertoldo, E., Tedesco, F., et al. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/7cinzu · Cited by 13
Self-citationFrench National Diagnostic and Care Protocol for antiphospholipid syndrome in adults and children
Amoura, Z., Bader‐Meunier, B., Sollier, C. B. D., Bélot, A., Benhamou, Y., Bézanahary, H., Aubart, F. C., Costedoat-Chalumeau, N., Darnige, L., Drouet, L. O., et al. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.08.004 · Cited by 13
Forastiero, R. R., & Martinuzzo, M. E. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1080121 · Cited by 12
“As in a more recent paper [59], the male sex was also independently associated with an increased risk of thrombosis.”
BackgroundFailure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome
Dufrost, V., Risse, J., Kirchner, S., et al. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex086 · Cited by 12
Specker, C., Fischer‐Betz, R., & Dörner, T. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00759-6 · Cited by 12
Bała, M. M., Celińska‐Löwenhoff, M., Padjas, A., Szot, W., & Undas, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012169 · Cited by 12
Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome
Petri, M. (2019) · Hematology · doi:10.1182/hematology.2019000046 · Cited by 11
“A second longitudinal study included only triple-positive individuals and did not separately analyze risk of lupus anticoagulant alone.(38)”
BackgroundApixaban Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndrome: A Cohort Study
Sikorska, M., Chmiel, J., Papuga-Szela, E., Broniatowska, E., & Undas, A. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001578 · Cited by 10
Richter, P., Bădescu, M. C., Rezuș, C., Ouatu, A., Dima, N., Popescu, D., Burlui, A., Bratoiu, I., Mihai, I. R., & Rezuş, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011281 · Cited by 14
“TLR4 is a potential initiating factor of these processes [28,35,46,64,65].”
BackgroundWillis, R., Pierangeli, S. S., Jaskowski, T. D., Malmberg, E. M., Guerra, M. M., Salmon, J. E., Petri, M., Branch, D. W., & Tebo, A. E. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw065 · Cited by 11
Prevention and Treatment of Thrombotic Antiphospholipid Syndrome
Crowther, M. A., Legault, K., Garcia, D. A., Tektonidou, M. G., Ugarte, A., Bruce, I. N., Erkan, D., & Ruiz‐Irastorza, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-55442-6_11 · Cited by 12
News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination
Bettacchioli, É., Nafai, S., & Renaudineau, Y. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.06.002 · Cited by 11
Bhasin, N., Knoll, C. M., & Skeith, L. (2020) · Springer eBooks · doi:10.1007/978-3-030-48446-0_24 · Cited by 11
Wysokinska, E. M., & Ortel, T. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00020-0 · Cited by 11
Lambert, M., Brodovitch, A., Mège, J., Bertin, D., & Bardin, N. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103585 · Cited by 10
Dieudonné, Y., Lorenzetti, R., Rottura, J., Janowska, I., Frenger, Q., Jacquel, L., Vollmer, O., Carbone, F., Zhu, C., Luka, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54228-8 · Cited by 10
Current status and future prospects for the treatment of antiphospholipid syndrome
Marzooqi, A. A., Leone, A., Saleh, J. A., & Khamashta, M. A. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1178573 · Cited by 10
Simmons, D. P., Herskovits, A. Z., Battinelli, E. M., Schur, P. H., Lemire, S. J., & Dorfman, D. M. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0790 · Cited by 11
Treatment in thrombotic antiphospholipid syndrome: a review
Vadgama, T. S., Smith, A., & Bertolaccini, M. L. (2019) · Lupus · doi:10.1177/0961203319864163 · Cited by 10
Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome
Tripodi, A. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15056 · Cited by 10
Radin, M., Barinotti, A., Cecchi, I., Foddai, S. G., Rubini, E., Roccatello, D., Menegatti, E., & Sciascia, S. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208199 · Cited by 10
Anticoagulating patients with high-risk acquired thrombophilias
Skeith, L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.439 · Cited by 10
“The risk of initial thrombosis is higher when multiple APLA test results are positive and may be as high as 5% per year and 37% after 10 years for individuals with triple-positive results (positive LAC, aCL, and ab2GP1 antibodies).(22,23)”
BackgroundAnticoagulantes de acción directa en el síndrome antifosfolípido. Revisión sistemática
Girón-Ortega, J. A., & González, J. A. G. (2023) · Medicina Clínica · doi:10.1016/j.medcli.2023.03.011 · Cited by 9
Antiphospholipid syndrome in children
Avramovič, M. Z., & Avčin, T. (2024) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2024.101986 · Cited by 11
“Positivity in all three aPL subtypes is called triple positivity and is the strongest predictor of thrombosis [14].”
Peleg, H., Naparstek, Y., Regola, F., Tincani, A., Pengo, V., & Denas, G. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102408 · Cited by 10
Self-citationPontara, E., Cattini, M. G., Bison, E., Cheng, C., Denas, G., & Pengo, V. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.08.004 · Cited by 9
Self-citationOgrič, M., Žigon, P., Sodin‐Šemrl, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010211 · Cited by 9
Lupus Anticoagulant Detection under the Magnifying Glass
Molinari, A. C., Martini, T., Banov, L., Ierardi, A., Leotta, M., Strangio, A., & Santoro, R. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206654 · Cited by 9
Risk factors of first thrombosis in obstetric antiphospholipid syndrome
Luo, L., Cai, Q., Liu, X., Hou, Y., & Li, C. (2024) · Lupus Science & Medicine · doi:10.1136/lupus-2023-001044 · Cited by 9
“Maternal hypercoagulability can persist until approximately 12 weeks after delivery.”
BackgroundMüller-Calleja, N., Ruf, W., & Lackner, K. J. (2024) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2024.2305121 · Cited by 11
Interpretation of laboratory data and need for reference laboratories
Pengo, V., Denas, G., Banzato, A., Bison, E., Bracco, A., Visentin, M. S., Hoxha, A., & Ruffatti, A. (2012) · Lupus · doi:10.1177/0961203312437271 · Cited by 9
Self-citationAnderson, M., & Belmont, M. H. (2022) · Lupus · doi:10.1177/09612033221074920 · Cited by 9
“3% per year, triple positive APS is associated with the highest risk.(7) After a first thrombotic event, the risk of recurrences sharply increases by 10–67%.”
BackgroundShusterman, M., Golub, E., Mowrey, W. B., & Broder, A. R. (2017) · Lupus · doi:10.1177/0961203317721352 · Cited by 9
Laboratory tests in rheumatology: A rational approach
Suresh, E. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18076 · Cited by 9
The Complex Relationship between C4b-Binding Protein, Warfarin, and Antiphospholipid Antibodies
Grosso, G., Sandholm, K., Antovič, A., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1347-5655 · Cited by 8
Qushmaq, N. A., & Al-Emadi, S. A. (2014) · ISRN Rheumatology · doi:10.1155/2014/348726 · Cited by 8
Sciascia, S., Radin, M., Cecchi, I., Fenoglio, R., Marchi, A. D., Besso, L., Baldovino, S., Rossi, D., Miraglia, P., Rubini, E., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-019-00698-9 · Cited by 8
Aguirre-Alastuey, M. E., Suárez, A., Rodríguez-Jerez, F., et al. (2020) · Lupus · doi:10.1177/0961203320967407 · Cited by 8
Antiphospholipid Syndrome in Patients with Venous Thromboembolism
Pengo, V., & Denas, G. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1749590 · Cited by 8
Self-citationMalhotra, P., Singh, C., Jain, A., & Tandon, R. (2023) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1858_21 · Cited by 8
Identification of the binding site for fondaparinux on Beta2-glycoprotein I
Kolyada, A. Y., Biasio, A. D., & Beglova, N. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.06.009 · Cited by 8
Dufrost, V., Darnige, L., Reshetnyak, T. M., et al. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00901-y · Cited by 8
Risk Assessment and Antithrombotic Strategies in Antiphospholipid Antibody Carriers
Calcaterra, I. L., Ambrosino, P., Vitelli, N., Lupoli, R., Orsini, R. C., Chiurazzi, M., Maniscalco, M., & Minno, M. N. D. D. (2021) · Biomedicines · doi:10.3390/biomedicines9020122 · Cited by 9
“In addition to the aforementioned scores, a number of traditional risk factors for thrombosis should also be considered for a more accurate risk management in aPL carriers [5].”
BackgroundResultHoughton, D. E., & Moll, S. (2017) · Vascular Medicine · doi:10.1177/1358863x17737374 · Cited by 9
Zuo, Y., Fan, J., Sarode, R., Zhang, S., Makris, U. E., Karp, D. R., & Shen, Y.-M. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618755946 · Cited by 7
“On the contrary, a study of 104 aPL-positive patients showed that when combining the arterial risks of HTN, diabetes, hyperlipidemia, obesity, smoking, and family history as one independent variable, its presence was not associated with thrombosis.(21) However, due to the low event rate and generalization of arterial…”
ResultZhou, Y., Hu, C., Qi, W., Long, Y., Huang, C. L., Wang, Q., Tian, X., Zhao, J., Li, M., & Zeng, X. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000924 · Cited by 7
“4 Individuals with triple aPLs positivity also showed increased risk of thrombosis in asymptomatic aPL carriers, 5 as well as patients with APS.”
Foret, T., Dufrost, V., Lagrange, J., et al. (2024) · Current Rheumatology Reports · doi:10.1007/s11926-024-01140-1 · Cited by 7
“However, in patients considered at high risk of thrombosis especially with triple positivity (LA positivity + aCL positivity IgG or IgM + aβ2-GPI positivity IgG or IgM) [25, 26], some studies showed a decrease in ETP and thrombin peak [27–29].”
Lin, T., Hsu, P.-Y., Chang, C., Ko, C., Kuo, Y., Wu, Y., Yen, R., Wu, C.-H., Li, K., Hsein, Y.-C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182344 · Cited by 7
Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies
Radin, M., Barinotti, A., Foddai, S. G., Cecchi, I., Rubini, E., Roccatello, D., Menegatti, E., & Sciascia, S. (2021) · Immunologic Research · doi:10.1007/s12026-021-09208-1 · Cited by 7
Marco, A., & Marco, P. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1767728 · Cited by 7
Specker, C. (2016) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-016-0153-8 · Cited by 7
Akikusa, J., & Choo, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00010-7 · Cited by 7
Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome
Riva, N., & Gatt, A. (2019) · EMJ Rheumatology · doi:10.33590/emjrheumatol/10314116 · Cited by 7
Khamashta, M. A., & Amigo, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00139-x · Cited by 8
Antiphospholipid Syndrome and Kidney Involvement
Simone, E. D., Sciascia, S., Fenoglio, R., Oddone, V., Barreca, A., & Roccatello, D. (2023) · Kidney & Blood Pressure Research · doi:10.1159/000529229 · Cited by 11
Mittal, P., Pacheco, M., Trives-Folguera, L., et al. (2024) · Lupus · doi:10.1177/09612033241266989 · Cited by 6
Scoring Systems for Estimating the Risk of Recurrent Venous Thromboembolism
Nichele, I., & Tosetto, A. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1602662 · Cited by 6
Freed, J. A., & Bauer, K. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00014-5 · Cited by 6
Moore, G. W., Foxton, E., Platton, S., Yartey, N., White, D., & MacDonald, S. G. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.08.009 · Cited by 6
Zen, M., Tonello, M., Favarò, M., Ross, T. D., Calligaro, A., Giollo, A., Vesentini, F., Gennaio, I. A., Arru, F., Ruffatti, A., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead517 · Cited by 6
Self-citationTop 10 Clinical Research Developments in Antiphospholipid Syndrome
Barbhaiya, M., & Erkan, D. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0367-6 · Cited by 6
The association of serum antiphospholipid antibodies and dilute Russell's viper venom times
Froom, P., Saffuri-Elias, E., Rozenberg, O., & Barak, M. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201830 · Cited by 6
An Integrated Soft Computing Approach to Hughes Syndrome Risk Assessment
Vilhena, J., Martins, M. R., Vicente, H., Grañeda, J. M., Caldeira, F., Gusmão, R., Neves, J., & Neves, J. (2017) · Journal of Medical Systems · doi:10.1007/s10916-017-0688-5 · Cited by 6
“Indeed, some studies reported that patients with triple positivity for aCL , a β 2 GPI and LA , exhibited a greater risk of thrombotic events than those who presented one or two positive antibodies [10,36].”
BackgroundZamora-Medina, M. D. C., Hinojosa‐Azaola, A., Núñez‐Álvarez, C. A., Vargas-Ruíz, Á. G., & Romero‐Díaz, J. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4381-y · Cited by 8
Lavoipierre, V., Talbot, M., Soubrier, C., Marie, B. D. S., Seux, V., Solas, C., Morange, P., Bernit, E., Ebbo, M., Faucher, B., et al. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2019.09.003 · Cited by 6
Analytical dilemmas in lupus anticoagulant detection
Moore, G. W. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00104 · Cited by 5
Alfehaid, L., Alsuhebany, N., Albahlal, H. N., Alomran, A., Alshehri, A. M., Alsheef, M. A., & Almutairi, A. R. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251364269 · Cited by 5
Chezel, J., Fischer, Q., Roland, P. N., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.003 · Cited by 5
Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome
Efthymiou, M., Bertolaccini, M. L., & Cohen, H. (2024) · Rheumatology · doi:10.1093/rheumatology/kead623 · Cited by 5
Antiphospholipid antibodies as potential prognostic indicators of recurrent ischemic stroke
Geng, L., Pan, K., Xu, Y., Zhang, B., Wang, J., Xue, Q., Zhang, S., Su, H., & Zhang, B. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107885 · Cited by 7
Summary of the 9th meeting of the European Forum on Antiphospholipid Antibodies
Swadźba, J., Sydor, W., Kołodziejczyk, J., & Musiał, J. (2014) · Lupus · doi:10.1177/0961203314520841 · Cited by 5
Ballul, T., Mageau, A., Nicaise‐Roland, P., Ajzenberg, N., Strukov, A., Dossier, A., Rouzaud, D., Papo, T., & Sacré, K. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.02.005 · Cited by 6
Neto, E. D. D. S., Neto, T. R., Signorelli, F., et al. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06613-9 · Cited by 5
Metadata
- Authors
- Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., Bison, E., Denas, G., Banzato, A., Padayattil Jose, S., & Iliceto, S.
- Affiliations
- Departments of Clinical Cardiology and
- University of Padua (IT)
- University of Bologna (IT)
- District Hospital, Cremona, Italy;
- University of Perugia (IT)
- University of Cagliari (IT)
- Transfusion Medicine, District Hospital, Merate, Italy; and
- Santa Maria Nuova Hospital (IT)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-10-27
- Volume
- 118
- Issue
- 17
- Pages
- 4714-4718
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1975074770
- Cited by
- 468
- References
- 28
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 35 · 2023: 36 · 2022: 18 · 2021: 41 · 2020: 46 · 2019: 42 · 2018: 39 · 2017: 38 · 2016: 29 · 2015: 23 · 2014: 33 · 2013: 28 · 2012: 28
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- antiphospholipid antibodies, thromboembolic events, lupus anticoagulant, anticardiolipin antibodies, anti-beta2-glycoprotein I antibodies, triple positivity, venous thromboembolism, aspirin, primary thromboprophylaxis, risk factors, male sex, incidence
- MeSH terms
- Adolescent, Adult, Aged, Disease Susceptibility, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Risk Factors, Thromboembolism, Incidence, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Early Diagnosis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
